Addex Therapeutics Ltd represents a set of core values and a corporate philosophy that guide its operations. The company is committed to scientific excellence, innovation, and patient-centricity in the field of drug discovery and development. Addex Therapeutics strives to improve the lives of patients by developing novel oral small molecules targeting specific biological pathways. With a focus on therapeutic areas such as neurology and immunology, the company aims to deliver innovative solutions to unmet medical needs. By fostering collaboration and leveraging its expertise, Addex Therapeutics is dedicated to advancing the frontiers of medicine and bringing transformative therapies to patients worldwide.

Addex Therapeutics Ltd is primarily present in multiple countries and regions worldwide. The company has a global presence with a focus on key markets such as the United States, Europe, and Asia. By expanding its reach across these regions, Addex Therapeutics Ltd aims to maximize its market potential and cater to a diverse range of customers. With its presence in multiple countries and regions, Addex Therapeutics Ltd is well-positioned to capitalize on emerging opportunities and strengthen its position as a leading player in the pharmaceutical industry.

Addex Therapeutics Ltd has achieved significant milestones in its industry. The company successfully developed and advanced its allosteric modulator drugs, targeting various diseases such as Parkinson's disease and schizophrenia. Addex Therapeutics also achieved notable progress in its clinical development programs, conducting successful Phase II trials for its lead candidate, dipraglurant, in Parkinson's disease levodopa-induced dyskinesia. The company has further strengthened its position through collaborations with industry-leading partners to expedite the development and commercialization of its innovative therapies. With its commitment to scientific excellence and strong pipeline, Addex Therapeutics Ltd continues to make remarkable strides in the field of allosteric modulation for the benefit of patients and investors.

Addex Therapeutics Ltd is a biopharmaceutical company with a rich history and background in the field of neuroscience. Founded in 2002, Addex has constantly been working towards the development of innovative therapeutic solutions for diseases such as Parkinson's and Schizophrenia. The company has a strong focus on modulating specific receptors in the brain to target and treat these conditions. With a dedicated team of scientists and researchers, Addex Therapeutics has made significant advancements in drug discovery and has several promising compounds in its pipeline. The company's commitment to improving the lives of patients and its relentless pursuit of groundbreaking therapies has positioned Addex as a leading player in the biopharmaceutical industry.

The main competitors of Addex Therapeutics Ltd in the market are other biopharmaceutical companies involved in the development and commercialization of novel therapies and treatments targeting similar disease areas. Some key competitors include AbbVie Inc., Alkermes plc, Eli Lilly and Company, and Johnson & Johnson.

Addex Therapeutics Ltd is primarily active in the pharmaceutical industry.

The business model of Addex Therapeutics Ltd revolves around developing novel oral small molecules for diseases that are currently not well-treated or have a significant unmet medical need. They focus on targeting specific proteins in the central nervous system (CNS) to address therapeutic gaps within neurological disorders and addiction-related diseases. Addex Therapeutics utilizes its proprietary drug discovery platform, allosteric modulation technology, to create innovative therapies. By leveraging their expertise, Addex Therapeutics aims to bring forth effective and safe treatment options to improve patients' lives and generate value for their shareholders.

Hệ số P/E của Addex Therapeutics là -1,28.

Chỉ số P/S của Addex Therapeutics là 3,16.

Chỉ số chất lượng AlleAktien của Addex Therapeutics là 2/10.

Doanh thu của kỳ vọng Addex Therapeutics là 1,22 tr.đ. CHF.

Lợi nhuận kỳ vọng Addex Therapeutics là -3,01 tr.đ. CHF.

Addex Therapeutics Ltd is a biopharmaceutical company specialized in the development of novel orally available drugs for the treatment of central nervous system diseases, as well as inflammatory and metabolic diseases. The company has developed a unique drug design and screening platform system focusing on allosteric modulators to selectively and effectively develop drugs. Addex Therapeutics operates in three main areas: clinical development programs, preclinical development programs, and partnerships with third parties. In the clinical development programs, Addex Therapeutics has various drug candidates in clinical development or near the start of clinical trials. The company works closely with contract research organizations to conduct these studies and ensure the safety and efficacy of the drug candidates. Addex Therapeutics' clinical development programs include the following drug classes: - ADX10059: A calcium channel modulator that offers an alternative therapy for the treatment of chronic migraine and gastroesophageal reflux disease. - ADX71149: A GABAB receptor modulator that represents a potential treatment option for schizophrenia and alcoholism. - ADX71441: A G-protein coupled receptor modulator that represents a potential treatment option for anxiety disorders. In the preclinical development programs, Addex Therapeutics is working on the development of drug candidates in the earliest phase of the development process. These drug candidates are still in early research and are being tested in vitro and in vivo to determine their potential for further development in later research stages, considering safety and efficacy. Addex Therapeutics has a wide range of technologies for drug discovery. The company utilizes various technologies to effectively shape drug design. Allosteric modulation is at the core of Addex Therapeutics' drug design system, allowing the company to selectively target specific targets within cells and tissues that play a role in various diseases. In partnerships with third parties, Addex Therapeutics collaborates with other companies or academic partners to further develop its drug candidates or develop new technologies. Addex Therapeutics has signed several agreements with leading biotech and pharmaceutical companies to expand the use of allosteric modulators. In addition to its drug candidates, Addex Therapeutics also offers drug discovery services. The company provides its customers with access to its technology platform to identify new drug candidates and accelerate drug development. These services are an important part of Addex Therapeutics' business model and contribute to the company's growth and diversification. Overall, Addex Therapeutics has a unique business model based on the development of novel drugs targeting specific targets within cells and tissues. With its technology platform and broad expertise in drug development, the company is able to efficiently and effectively navigate its drug candidates through clinical development. Addex Therapeutics' strategic partnerships and drug discovery services provide additional growth opportunities. Translation provided by a language model trained on a mixture of professional translations and publicly available data.

Addex Therapeutics cổ tức hàng năm là 0 CHF, được phân phối qua lần thanh toán trong năm.

Hiện tại không thể tính toán được cổ tức cho Addex Therapeutics hoặc công ty không chi trả cổ tức.

Mã ISIN của Addex Therapeutics là CH0029850754.

Mã WKN của Addex Therapeutics là A0MSH6.

Mã chứng khoán của Addex Therapeutics là ADXN.SW.

Trong vòng 12 tháng qua, Addex Therapeutics đã trả cổ tức là . Điều này tương đương với lợi suất cổ tức khoảng . Dự kiến trong 12 tháng tới, Addex Therapeutics sẽ trả cổ tức là 0 CHF.

Lợi suất cổ tức của Addex Therapeutics hiện nay là .

Addex Therapeutics trả cổ tức hàng quý. Số tiền này được phân phối vào các tháng .

Addex Therapeutics đã thanh toán cổ tức hàng năm trong 0 năm qua.

Trong 12 tháng tới, người ta kỳ vọng cổ tức sẽ đạt 0 CHF. Điều này tương đương với tỷ suất cổ tức là 0 %.

Addex Therapeutics được phân loại vào ngành 'Sức khỏe'.

Để nhận được cổ tức cuối cùng của Addex Therapeutics vào ngày 18/8/2024 với số tiền 0 CHF, bạn phải có cổ phiếu trong tài khoản trước ngày không hưởng quyền vào 18/8/2024.

Việc thanh toán cổ tức cuối cùng đã được thực hiện vào 18/8/2024.

Vào năm 2023, Addex Therapeutics đã phân phối 0 CHF dưới hình thức cổ tức.

Cổ tức của Addex Therapeutics được phân phối bằng CHF.